What was the price per share for Peter C. Farrell’s ResMed (RMD) stock sale?

The reported sale price was $251.31 per share of ResMed common stock. This price is shown in the Form 4 as the transaction price for the 2,000 shares sold on February 4, 2026.

ResMed (RMD) director Peter Farrell sells 2,000 shares in 10b5-1 trade

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

ResMed Inc. director Peter C. Farrell, who serves as chairman emeritus, reported selling 2,000 shares of ResMed common stock on February 4, 2026 at a price of $251.31 per share. After this transaction, he beneficially owned 64,773 shares directly. The sale was executed under a pre‑arranged Rule 10b5‑1 trading plan that was adopted on August 12, 2025, indicating the trade followed an advance, systematic plan rather than a discretionary same‑day decision.

Insights

ResMed director sells 2,000 shares via pre‑set 10b5‑1 plan.

Peter C. Farrell, a director and chairman emeritus of ResMed Inc., sold 2,000 shares of ResMed common stock on February 4, 2026 at $251.31 per share. Following this sale, he directly held 64,773 shares.

The filing notes the transaction occurred under a Rule 10b5‑1 plan adopted on August 12, 2025. Such plans typically automate trades according to preset instructions, reducing the likelihood that the timing reflects new, undisclosed information.

As only one transaction is disclosed and the director retains a substantial shareholding, this looks like a routine, pre‑planned disposition rather than a transformative governance or ownership shift. Subsequent company filings may provide additional context if further plan trades occur.

Insider Trade Summary

Net Seller: 2,000 shares ($502,620)

Net Sell 1 txn

Insider FARRELL PETER C

Role Director

Sold 2,000 shs ($503K)

Type	Security	Shares	Price	Value
Sale	ResMed Common Stock	2,000	$251.31	$503K

Holdings After Transaction: ResMed Common Stock — 64,773 shares (Direct)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

02/06/2026 - 11:07 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FARRELL PETER C

(Last)

(First)

(Middle)

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO

92123

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock	02/04/2026		S⁽¹⁾		2,000	D	$251.31	64,773	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.

	/s/ Peter C. Farrell, Chairman emeritus	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ResMed (RMD) report for Peter C. Farrell?

ResMed director Peter C. Farrell reported selling 2,000 shares of ResMed common stock. The sale occurred on February 4, 2026 at a price of $251.31 per share, as disclosed in a Form 4 insider trading report.

How many ResMed (RMD) shares does Peter C. Farrell own after this Form 4 sale?

After selling 2,000 shares, Peter C. Farrell beneficially owns 64,773 shares of ResMed common stock directly. This remaining position is disclosed in the Form 4 as his direct ownership following the reported transaction.

Was the ResMed (RMD) insider sale by Peter C. Farrell pre-planned under Rule 10b5-1?

Yes. The Form 4 states the transaction was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025. This indicates the sale followed pre-established instructions rather than a discretionary trade made on the transaction date.

What role does Peter C. Farrell hold at ResMed (RMD) in this Form 4 filing?

In the Form 4, Peter C. Farrell is identified as a director of ResMed Inc. and signs the report as chairman emeritus. The filing also confirms he is not listed as a 10% owner or an officer of the company.

Is Peter C. Farrell’s ownership in ResMed (RMD) direct or indirect after the transaction?

The Form 4 indicates that Peter C. Farrell’s 64,773 shares of ResMed common stock are held with direct ownership. The ownership form column lists the holding as “D” for direct, with no indirect ownership entity described.